Start with the real problem
You’re not buying stats for the sake of it — you’ve got endpoints to protect, regulators to satisfy and a trial timeline that won’t wait. Say the study’s on treatments for urinary conditions; you might already be lining up a preclinical CRO urology partner. The spec has to make the problem obvious: what hypotheses will fail the team if the analysis is wrong, which comparisons are primary, and which results will determine go/no-go decisions.
Define measurable objectives, not vague wishes
Write objectives as testable statements. Replace “assess efficacy” with “compare mean change in eGFR at 24 weeks between treatment and placebo, adjusting for baseline eGFR and site.” List primary and secondary endpoints, the estimands you need, and the minimum clinically important difference you’ll accept. Clear objectives force the CRO to propose appropriate models and sample sizes instead of generic analyses.
Match methods to trial risks
Consider what would ruin your readout: missing data, multiplicity, heterogeneous sites, or skewed biomarkers. For each risk, require methods up front — e.g., mixed models for repeated measures, pre-specified multiplicity control, sensitivity analyses for missing-not-at-random. Ask for code-ready statistical analysis plans (SAPs) with annotated mock tables so nothing’s left to interpretation on lock.
Power and sample-size: be specific about assumptions
Demand transparent calculations. Provide the assumed control event rate or variance, the effect size you care about, alpha, power, and planned interim looks. Require the CRO to deliver a holdout appendix showing how sample size shifts if key assumptions move ±10–20%. That’s practical: you’ll spot fragile designs before you commit.
Programming standards and reproducibility
Insist on software and workflow details. Specify preferred statistical packages (SAS, R), coding standards, version control, and whether outputs must be reproducible from raw datasets. Ask for a reproducible package or script set that re-creates tables and figures from the locked dataset — that prevents late-night “it ran on my machine” dramas.
EEAT: show you know the field and expect the same
Bring expertise to the table so the CRO can match it. Referencing a high-level, widely recognized anchor like the Global Burden of Disease 2019 findings on chronic kidney disease prevalence helps show you understand clinical impact and population scale; pair that with a specific in vivo platform if relevant, for example a CKD model, and you set an expectation that the stats plan aligns with real biology. List team credentials, prior trials or published analyses you expect to be emulated, and require named statisticians on the CRO side with comparable experience.
Common mistakes to avoid
Don’t let the spec leave ambiguity on primary estimands, handling of intercurrent events, or multiplicity. Avoid one-line SAPs, vague deliverable timelines, and “standard methods” clauses with no detail. Don’t defer critical decisions to meetings after database lock — those are where scope creep and disputes start.
Vendor selection checklist
Score vendors on these concrete items: regulatory experience in your target markets, examples of SAPs and mock shells, availability of biostatisticians during critical windows, version-controlled code delivery, and timelines for interim analyses. Ask for a redacted case study showing a similar trial where they handled missing data or complex randomisation. If a vendor can’t show reproducible code or named personnel, move on.
Contracts and deliverables — make them ironclad
Spell out deliverables by name and date: draft SAP, final SAP, interim analysis report, blinded review documents, frozen datasets, validated code, and regulatory-ready tables/figures. Define acceptance criteria for outputs and penalties for missed milestones. Require audit trails and access for inspectors to raw datasets and analysis scripts.
Compare alternatives and choose pragmatically
Big CROs bring process and templates, boutique teams bring flexibility and attention. Use big firms when regulatory heft and global submissions matter. Pick smaller groups when you need rapid, bespoke analytics or close collaboration with biostatisticians. Whatever you pick, insist they prove delivery on a similar problem — nothing judges capability like a past win on a comparable endpoint or model.
Wrap-up that actually helps you move forward
Specify objectives, lock methods for key risks, require transparent power calculations, demand reproducible code, and make deliverables contractual. Those actions prevent firefighting late in development. If you need a partner who understands both in vivo platforms and rigorous biostatistics, check how partners position their science and code, and you’ll see where the real value sits with KCI Biotech.